Table 6.
Effect on laboratory parameters in both the groups
| Laboratoryparameters | IG (n=25) | CG (n=27) | P # |
|---|---|---|---|
| Total leucocyte count (103/µL) | |||
| Baseline | 6.04±1.78 | 5.89±1.42 | 0.736 |
| 30th day | 6.56±1.57 | 6.93±1.98 | 0.459 |
| P$ | 0.091 | 0.008* | |
| Neutrophils(%) | |||
| Baseline | 57.4±11.16 | 58.7±8.83 | 0.641 |
| 30th day | 60.28±8.76 | 58.44±6.60 | 0.396 |
| P$ | 0.194 | 0.871 | |
| Lymphocytes(%) | |||
| Baseline | 34.04±11.54 | 32.85±8.67 | 0.675 |
| 30th day | 31.32±8.71 | 33.51±6.73 | 0.311 |
| P$ | 0.203 | 0.681 | |
| Eosinophils(%) | |||
| Baseline | 2.84±1.06 | 3.29±1.97 | 0.311 |
| 30th day | 3.6±2.23 | 3.37±1.64 | 0.673 |
| P$ | 0.103 | 0.854 | |
| Absolute lymphocyte count (per mm3) | |||
| Baseline | 1992.88±669.35 | 1897.03±540.39 | 0.571 |
| 30th day | 2099.4±673.12 | 2300.5±693.93 | 0.295 |
| P$ | 0.451 | <0.001* | |
| ESR (mm/h) | |||
| Baseline | 17.6±9.97 | 20.55±11.90 | 0.338 |
| 30th day | 21.44±9.62 | 18.51±10.68 | 0.307 |
| P$ | 0.070 | 0.348 | |
| D-dimer (µg/mL)a | |||
| Baseline | 233.8 (173.9 628.3) | 250.0 (157.8 293.7) | 0.782 |
| 30th day | 185.0 (129.4 263.7) | 132.0 (84.7 213.5) | 0.055 |
| P$ | 0.015* | 0.005* | |
| IL-6 (pg/mL)a | |||
| Baseline | 5.6 (2.3 13.8) | 3.6 (1.7 4.8) | 0.067 |
| 30th day | 1.9 (0.15 5.3) | 0.4 (0.2 6.6) | 0.905 |
| P$ | 0.037* | 0.361 | |
| TNF-α (pg/mL) | |||
| Baseline | 5.70±2.15 | 5.58±1.32 | 0.809 |
| 30th day | 4.13±1.85 | 6.48±4.14 | 0.012* |
| P$ | 0.014* | 0.318 |
*P<0.05 has been considered as significant, aData have been reported as median (Q1-Q3), #Between group P value, compared using independent sample t-test/Mann-Whitney test, $Within group P value, compared using paired sample t-test/Wilcoxon signed-rank test. Values have been represented as mean±SD. IG: Intervention group, CG: Control Group, ESR: Erythrocyte sedimentation rate, IL-6: Interleukin-6, TNF-α: Tumor necrosis factor-α, SD: Standard deviation